Alnylam Defends Heart Disease Drugs Following AstraZeneca's Wainua Trial Failure

Revelation News Editorial DeskAugust 30, 2026

Source Summary

AstraZeneca's Wainua heart disease trial has failed, creating pressure on Alnylam to defend its own medicines in the same therapeutic area. Alnylam is mounting a defense of its heart disease drug candidates in response to the trial setback.

Why it matters

The failure of a competitor's heart disease trial raises questions about the viability of similar drug approaches, directly affecting investor confidence in Alnylam's pipeline in this therapeutic area.

Read the Source

STAT News ↗

NASDAQ:ALNYLive chart

Trading trends

The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.

Recent SEC-reported share and derivative transactions in ALNYLAM PHARMACEUTICALS, INC..

Insider activity sentiment

Leaning bearish

BearishNeutralBullish

0 discretionary purchases · 1 discretionary sales

Confidence: Low

Informative buyNon-informative buyInformative sellNon-informative sell

Insiders	Activity	Description	Shares	Avg. price / share	Est. value	Trade date
EVP, CLO and SecretarySUPRAN BRYAN	Informative sell	Common StockOpen-market or private transaction (S)	1,758	$226.88	$398,855	Oct 2, 2026
Chief Executive OfficerGreenstreet Yvonne	Non-informative buy	Common StockCompany grant or award (A)	107	—	—	Sep 19, 2026
DirectorPYOTT DAVID E I	Non-informative sell	Common StockReported 10b5-1 plan (S)	921	$297.71	$274,191	Jun 1, 2026
DirectorPYOTT DAVID E I	Non-informative sell	Common StockReported 10b5-1 plan (S)	1,175	$298.91	$351,219	Jun 1, 2026
DirectorPYOTT DAVID E I	Non-informative sell	Common StockReported 10b5-1 plan (S)	1,222	$299.87	$366,441	Jun 1, 2026

As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.

Short interest

Open short positions reported twice monthly; this is not daily short-sale volume.

Earnings

Recent reported earnings per share compared with the analyst consensus available from Nasdaq.

Comments

No published comments yet.

Owner	Activity	Change	Shares held	Value (thousands)	Reported
Fmr Llc	Buy	444,796 (3.051%)	15,023,962	$3,414,646	6/30/2026
Vanguard Group Inc	Sell	-11,520 (-0.085%)	13,553,932	$3,080,538	12/31/2025
Capital World Investors	Buy	342,498 (3.171%)	11,144,846	$2,533,001	6/30/2026
Blackrock, Inc.	Buy	462,767 (4.431%)	10,907,675	$2,479,096	6/30/2026
Capital Research Global Investors	Buy	279,518 (2.951%)	9,750,699	$2,216,139	6/30/2026
Vanguard Portfolio Management Llc	Buy	47,110 (0.726%)	6,538,390	$1,486,045	6/30/2026
Vanguard Capital Management Llc	Buy	82,772 (1.392%)	6,029,478	$1,370,380	6/30/2026
T. Rowe Price Investment Management, Inc.	Buy	448,849 (8.643%)	5,642,173	$1,282,353	6/30/2026
Invesco Ltd.	Sell	-320,802 (-7.872%)	3,754,318	$853,281	6/30/2026
State Street Corp	Buy	232,991 (7.012%)	3,555,689	$808,137	6/30/2026
Jpmorgan Chase & Co	Sell	-3,648,235 (-57.691%)	2,675,517	$608,092	6/30/2026
Geode Capital Management, Llc	Sell	-24,545 (-0.923%)	2,635,840	$599,074	6/30/2026

Settlement date	Short interest	Avg. daily volume	Change vs. previous report	Days to cover
Sep 30, 2026	7,711,495	1,195,107	+7.19%	6.45
Sep 15, 2026	7,194,097	1,742,234	+13.47%	4.13
Aug 31, 2026	6,340,087	1,625,574	+32.89%	3.90
Aug 14, 2026	4,770,978	2,018,399	-0.67%	2.36
Jul 31, 2026	4,803,194	2,204,446	-16.80%	2.18
Jul 15, 2026	5,773,373	1,782,477	-0.46%	3.24
Jun 30, 2026	5,799,788	1,373,085	+6.67%	4.22
Jun 15, 2026	5,437,337	1,142,712	—	4.76

Fiscal quarter	Reported	EPS	Consensus	Surprise
Jun 2026	Jul 30, 2026	1.21	1.44	-15.97%
Mar 2026	Apr 30, 2026	1.51	0.91	+65.93%
Dec 2025	Feb 12, 2026	0.82	0.75	+9.33%
Sep 2025	Oct 30, 2025	1.84	0.46	+300%

Source Summary

Why it matters

Read the Source

NASDAQ:ALNY — Live chart

Insider activity sentiment

Comments

Related stories

Alnylam's Cardiac Drug Program Faces Scrutiny at European Cardiology Congress

Alnylam's Amvuttra data support efficacy across ATTR patient groups

Summit Therapeutics shares surge after-hours following $2 billion AstraZeneca equity investment

Comments

Insider activity sentiment

NASDAQ:ALNYLive chart